University of Chicago Medicine-Orland Park — Orland Park, Illinois

Public research footprint of University of Chicago Medicine-Orland Park, compiled from the ClinicalTrials.gov public registry.

149

Registered studies

119

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Recurrent Endometrial Carcinoma · Locally Advanced Malignant Solid Neoplasm · Stage IB Lung Non-Small Cell Carcinoma AJCC v7 · Lung Non-Squamous Non-Small Cell Carcinoma

Recently updated registry entries

NCT03712605 — Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After… (Active Not Recruiting)
NCT05600894 — Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic… (Active Not Recruiting)
NCT06589804 — Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at University of Chicago Medicine-Orland Park?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.